Skip to main content

Table 1 Population characteristics. Placebo (PLA) group and lidocaine (LIDO) group, data as mean ± SD or n (%)

From: Intravenous lidocaine to prevent endothelial dysfunction after major abdominal surgery: a randomized controlled pilot trial

 PLA (n = 20)LIDO (n = 20)
Age (years)60 ± 10.963 ± 12.5
Male gender10 (50)13 (65)
Weight (kg)74 ± 16.577 ± 14.2
BMI (kg/m2)26 ± 5.626 ± 4.9
ASA 11 (5)1 (5)
ASA 215 (75)12 (60)
ASA 34 (20)7 (35)
POSSUM (physiologic)16.9 ± 3.819.7 ± 4.1
POSSUM (operative)12.4 ± 4.511.4 ± 2.9
POSSUM predicted morbidity (%)32.4 ± 23.237.2 ± 18.6
POSSUM predicted mortality (%)6.4 ± 9.86.8 ± 6.0
Cardiac Risk (LEE criteria) (%)1.9 ± 2.41.4 ± 1.8
Comorbidities
 Arterial Hypertension9 (45)9 (45)
 Hypercholesterolemia4 (20)3 (15)
 Diabetis (typeI or II)3 (15)5 (25)
 Ischemic cardiopathy3 (15)2 (10)
 Other cardiopathy02 (10)
 Tobacco abuse6 (30)6 (30)
 Renal Insufficiency (KDIGO stage <3b)1 (5)3 (15)
 COPD3 (15)3 (15)
 Stroke or TIA1 (5)2 (10)
 Peripheral Arterial Disease1 (5)0
Medications
 Beta-blockers2 (10)7 (35)
 Ca-channel blockers2 (10)0
 ACE - inhibitors7 (35)4 (20)
 Nitrates00
 Oral Antidiabetic Agents1 (5)3 (15)
 Insuline2 (10)2 (10)
 Other Medications17 (85)11 (55)